Vir Biotechnology (VIR) Operating Leases (2020 - 2026)

Vir Biotechnology (VIR) has 7 years of Operating Leases data on file, last reported at $86.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 1.74% year-over-year to $86.6 million; the trailing twelve-month figure through Mar 2026 stood at $86.6 million (down 1.74% YoY), and the FY2025 full-year result was $89.1 million, down 9.03% from the prior year.
• Operating Leases retreated to $86.6 million in Q1 2026, from $89.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $132.8 million in Q1 2022 to a low of $86.6 million in Q1 2026.
• A 5-year average of $107.2 million and a median of $109.2 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases surged 99.37% in 2022 and decreased 19.35% in 2024, its largest moves.
• Tracing VIR's Operating Leases over 5 years: stood at $123.8 million in 2022, then slipped by 9.82% to $111.7 million in 2023, then slipped by 12.34% to $97.9 million in 2024, then slipped by 9.03% to $89.1 million in 2025, then retreated by 2.72% to $86.6 million in 2026.
• Business Quant data shows VIR's Operating Leases at $86.6 million in Q1 2026, $89.1 million in Q4 2025, and $91.2 million in Q3 2025.